Presentation is loading. Please wait.

Presentation is loading. Please wait.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Published byありさ こびき Modified over 4 years ago

Similar presentations

Presentation on theme: "A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan."— Presentation transcript:

1 A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. B, week 36 CT scan of the same patient showing regression of pelvic lymphadenopathy (identified by white arrow) meeting definition for a partial response. Glenn Liu et al. Clin Cancer Res 2002;8: ©2002 by American Association for Cancer Research

Download ppt "A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan."

Similar presentations

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.
Rearrangements of Gene A and Gene B

Rearrangements of Gene A and Gene B
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Axial CT scans of the chest. a) Before treatment

Axial CT scans of the chest. a) Before treatment
Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.

Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.
A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.
The frequency of documented pneumonia and risk of pneumonia by stroke severity on screening. The frequency of documented pneumonia and risk of pneumonia.

The frequency of documented pneumonia and risk of pneumonia by stroke severity on screening. The frequency of documented pneumonia and risk of pneumonia.
Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.
Correlation between MRP1 mRNA expression and CF efflux-blocking factors of MK-571 (A) and between MDR1 mRNA expression and Rh123 efflux-blocking factors.

Correlation between MRP1 mRNA expression and CF efflux-blocking factors of MK-571 (A) and between MDR1 mRNA expression and Rh123 efflux-blocking factors.
Effect of nucleoside analogues on DNA repair response initiated by 4-HC. Effect of nucleoside analogues on DNA repair response initiated by 4-HC. A, CLL.

Effect of nucleoside analogues on DNA repair response initiated by 4-HC. Effect of nucleoside analogues on DNA repair response initiated by 4-HC. A, CLL.
Contrast-enhancing lesions on CT scans (A–D) in 4 patients with AIDS-related PCNSL. Note irregularly enhancing lesions in the right parietal lobe (A),

Contrast-enhancing lesions on CT scans (A–D) in 4 patients with AIDS-related PCNSL. Note irregularly enhancing lesions in the right parietal lobe (A),
Illustration of a stably tethered structure made by the DNL method.

Illustration of a stably tethered structure made by the DNL method.
A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.
Frequent alterations identified and potential actionability.

Frequent alterations identified and potential actionability.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
Matriptase-2 inhibited breast tumor development in vivo.

Matriptase-2 inhibited breast tumor development in vivo.
Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Similar presentations

Ads by Google